Navigation Links
Aaron 900

ProductsAaron 900
Company Bovie Aaron Medical
Item Aaron 900
Features Aaron 900 comes with digital power control system, foot control, digital error detection and provides economy and quality. Low to high power by rotating the power control knob. No separate ports, no switching plugs. Rotary power-control dial provides smooth, rapid power adjustments. Autoclavable handpiece holds standard 3/32" (0.24cm) electrodes safely and securely. Use the same handpiece in footswitch mode. Output modes are clearly, logically marked and conveniently located.
Description The Aaron 900 high frequency desiccator forever removes the need to go through a tedious multi-step process to change from low to high power.
Info Bovie Aaron Medical
Customer Service: (800) 537-2790

Related medicine products :

1. Aaron Burr II
2. Aaron Burr 3
3. Aaron Burr 4
4. Aaron 1250
5. Aaron 2250
6. Aaron 800-EU
7. Aaron 950
8. Aaron 950 Electrosurgery Generator
9. Aaron 2250 Electrosurgery Generator
TAG: Aaron
The RX imola is a bench-top fully automated random access clinical analyser that offers a host of features usually only seen on larger systems. The RX imola has the capacity to perform up to 400 test
Inquire
...is a serum glycoprotein which binds several sex st...pacity, including testosterone and dihydrotestoste...esser extent, estradiol [1]. SHBG specifically bin...e bioavailability of sex steroids. SHBG is produce...
...long to the transforming growth factor- (TGF-) sup... extra-cellular growth factors which control many ...tumor formation (1). Other members incude TGF-s, b... factors, AMH/MIS (Anti-Mullerian Hormone/Mulleria...
Medicine Products:
(Date:9/5/2008)...re-USNewswire/ -- As the general election,campaign...of Independent,Business ( http://www.nfib.com ) is...greater focus on the healthcare concerns of small,...onventions are over, NFIB,is asking both candidate...d,by small businesses as they further develop thei...
(Date:9/5/2008)... meds on Web site shouldn,t overreact or stop taki...ews) -- The U.S. Food and Drug Administration has ...ted for potential safety issues, the agency said F...ort, it means we have begun analysis to determine ...rther evaluation," Dr. Gerald Dal Pan, director of...
(Date:9/5/2008)...k Fashion Week,s Annual Destination to Feature Vel...ork (PRWEB) September 5, 2008 -- http://www.amer...merican Laser], the largest provider of laser hair...in the U.S., announces sponsorship of the STYLE360...m Sept. 7-10, serves as the alternative Fashion We...
(Date:9/4/2008)...08Private Medicare Advantage (MA) plans will be pa...08 compared to what the same enrollee would have c...ogram, according to a new report from The Commonwe...lans mandated by the Medicare Improvements for Pat... to take effect beginning in 2010 had been fully ...
Breaking Medicine News(10 mins):Health News:Conventions Conclude, Fall Campaign Begins: NFIB Looks for More Focus on Small Business Healthcare Concerns 2Health News:Conventions Conclude, Fall Campaign Begins: NFIB Looks for More Focus on Small Business Healthcare Concerns 3Health News:FDA to List Drugs Under Review for Safety Issues 2Health News:American Laser Centers Sponsors STYLE360 to Share the Skinny on Body Shaping 2Health News:Extra payments to Medicare Advantage plans to total $8.5 billion in 2008 2
... study from researchers, steadfast and simple bloo...y detects diabetes in the doctor's surgery.// Arou...gnosed diabetesputting themselves at increased ris...ard test involves measuring blood sugar and requir...
...rm Australia have correlated a molecular 'switch' ...vels fall, a finding that could provide the basis ...nd heart attack.// A team from the University of A...ment and CSIRO Health Sciences and Nutrition repor...
...ith low-calcium diets, even a modest increase in t...of colon cancer. Researchers evaluated the diet an... two large health surveys.// They found that those... a day significantly reduced their risk of left-si...
...drug users often drifted off in the middle of sent...ld already.The drug cannabis people used,// the mo...s conclude. The findings come from one of the lar...act of recreational drugs on psychological functio...
Other Medicine News:Health News:A new recovery for heart attacks, 2
(Date:9/5/2008)...SNewswire/ -- The Florida,Technology, Research and...ic University researcher Dr. Herbert Weissbach, di...or Molecular Biology and,Biotechnology in the Char...es LLC (CHS), $184,294 as part of the State Univer...rogram (SURECAG). SURECAG was,established by the F...
(Date:9/5/2008)...USNewswire/ -- A team of,researchers at West Virgi...,India and Pakistan take on the habits of their ad...cancer among male immigrants and breast cancer,amo...evelop due to many reasons, but,environmental fact...rs,",said Jame Abraham, M.D., medical director for...
(Date:9/4/2008)...FirstCall/ -- BioForm Medical,Inc. (Nasdaq: BFRM... of,Polidocanol, conducted in Germany by BioForm M... GmbH (Kreussler), successfully met the study prim... of a New Drug Application,(NDA) process., In the...and safety of,Aethoxysklerol compared to Sodium Te...
(Date:9/4/2008)...-- Southern Research Institute,today announced tha...cted,the organization to participate in the newly-... Network (MLPCN). The MLPCN -- a collaborative,res...s Program which is,designed to benefit human healt...e and validate future targets for drug discovery.,...
Breaking Medicine Technology:Major State Grant Accelerates Research and Development of Novel Cancer Therapy 2Major State Grant Accelerates Research and Development of Novel Cancer Therapy 3Immigrants From India, Pakistan Face U.S. Prostate, Breast Cancer Risks 2338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 2338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 3338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 4338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 5Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 2Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 3Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 4American Elements Announces Expanded Bromide and Iodide Manufacturing Capacity 25672 1Five Steps for Staying in Financial Control with Long Term Disability 25667 1Five Steps for Staying in Financial Control with Long Term Disability 25667 2Five Steps for Staying in Financial Control with Long Term Disability 25667 3Five Steps for Staying in Financial Control with Long Term Disability 25667 4Resverlogix Notice of Conference Call 26 Webcast 7279 1Resverlogix Notice of Conference Call 26 Webcast 7279 2BioMarin Announces Roll Out of National PKU Registry 7278 1BioMarin Announces Roll Out of National PKU Registry 7278 2BioMarin Announces Roll Out of National PKU Registry 7278 3
...hering-Plough Corp. announced results,from a Phase...th,Caelyx (pegylated liposomal doxorubicin hydroch...n (TTP) in patients with,metastatic breast cancer ...fter first-line chemotherapy. These data were pres...ican Society of,Clinical Oncology. , ,"While stand...
...est Ever Phase III Clinical Trial in,Lung Cancer T...FirstCall/ --,GlaxoSmithKline today announced fina...trial of its investigational MAGE-A3,Antigen-Speci...itive patients with stage IB or II Non-Small Cell ...the 2007 American Society of,Clinical Oncology (AS...
Other Medicine Technology:Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 2Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 3Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 4Caelyx Delays Time to Disease Progression as Maintenance Therapy in,Patients with Metastatic Breast Cancer 5Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 2Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 3Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 4Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 5Encouraging Clinical Activity of GSK's Novel Cancer,Immunotherapeutic Confirmed in Phase II Study in Patients with Most,Common Form of Lung Cancer 6